Products Categories
| CAS No.: | 99614-02-5 |
|---|---|
| Name: | Ondansetron |
| Article Data: | 30 |
| Molecular Structure: | |
|
|
|
| Formula: | C18H19N3O |
| Molecular Weight: | 293.368 |
| Synonyms: | 1,2,3,4-Tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-9H-carbazol-4-one;GR 38032;GR 38032X;Ondanles;1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1h-imidazol-1-yl)methyl)-4h-carbazo;Zofran;Zophren;Zudan; |
| EINECS: | 619-449-4 |
| Density: | 1.27 g/cm3 |
| Melting Point: | 231 - 232oC |
| Boiling Point: | 546 °C at 760 mmHg |
| Flash Point: | 284 °C |
| Appearance: | White or almost White Powder |
| Hazard Symbols: |
 T, Xi
|
| Risk Codes: | 25-36/37/38 |
| Safety: | 45-37/39-26 |
| Transport Information: | UN 2811 6.1/PG 3 |
| PSA: | 39.82000 |
| LogP: | 3.12850 |
- 99724-17-1Dimethyl-pyrrolidin-3-ylmethyl-amine
- 99689-20-02-Acetamido-3-O-(D-1-carboxyethyl)-2-deoxy-2-D-glucose Methyl Ester
- 99662-46-1triphenyl(2-pyridylmethyl)phosphonium chloride hy
- 99735-47-4((R)-1-((R)-1-phenylethyl)pyrrolidin-3-yl)methanol
- 99735-45-2(R)-methyl 5-oxo-1-((R)-1-phenylethyl)pyrrolidine-3-carboxylate
- 99783-85-41-(3-hydroxy-4-methoxyphenyl)-3-methylbutan-1-one
- 99873-43-5Droxinostat
- 99614-70-7Carbazol-4-one hydrochloride
- 99914-14-42-CHLORO-5-AMINO-ACETOPHENONE
- 99971-84-34,6-dichloro-1-phenyl-1H-pyrazolo[3,4-d]pyrimidine
What can I do for you?
Get Best Price
Chemistry
The Molecular formula of Ondansetron (CAS NO.99614-02-5): C18H19N3O
The Molecular Weight of Ondansetron (CAS NO.99614-02-5): 293.37
The Molecular Structure of Ondansetron (CAS NO.99614-02-5):
Density: 1.27 g/cm3
Boiling point: 546 °C at 760 mmHg
Flash point: 284 °C
Solubility in water: H2O: >5 mg/mL
Index of Refraction:1.677
Molar Refractivity: 86.75 cm3
Molar Volume: 230.1 cm3
Surface Tension: 48.9 dyne/cm
Enthalpy of Vaporization: 82.5 kJ/mol
Vapour Pressure: 5.62E-12 mmHg at 25°C
IUPAC Name: 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one hydrochloride
Synonyms: 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1h-imidazol-1-yl)methyl)-4h-carbazo ; Gr 38032f ; Ondansetrone hydrochloride ; Ondansetron hcl ; Ondansetron hcl dihydrate ; Ondansetron hydrochloride dihydrate ; Gr38032
History
Ondansetron was developed around 1984 by scientists working at Glaxo's laboratories in London. It is in both the Imidazole and Carbazole families of heterocyclic compounds.After several attempts the company successfully filed for U.S. patent protection for the drug in 1986. U.S. Patent 4,695,578 was granted in September 1987 while U.S. Patent 4,753,789 was granted in June 1988. U.S. Patent 5,578,628, a divisional patent of U.S. Patent 4,753,789, was granted in November 26, 1996. Ondansetron was granted Food and Drug Administration (FDA) approval as Zofran in January 1991. Glaxo did pediatric research on Zofran's uses, and gained patent extension as a result. Consequently U.S. exclusivity ended December 24, 2006. The FDA subsequently approved the first generic versions in December 2006, with marketing approval granted to Teva Pharmaceuticals USA and SICOR Pharmaceuticals. It is currently marketed by GlaxoSmithKline (GSK) under the trade name Zofran; other manufacturers include Cipla Ltd. (Emeset), Gedeon Richter Ltd. (Emetron), Korea United Pharmaceuticals (Emodan), Zentiva a.s. (Ondemet) and Novell Pharmaceutical Laboratories (Ondavell). On May 29, 2006, Baxter Healthcare received tentative approval to market its own label of Ondansetron Injection, USP, 8 mg/50 mL and 32 mg/50 mL iso-osmotic sodium chloride solution, after GSK's patent expired on December 24, 2006.
Uses
It's 5 - hydroxytryptamine (5-HT3) receptor antagonist and efficient antiemetic drug, with high strength and a high degree of selectivity.It can control vomit which stimulate by receptor in the small intestine and the CTZ (chemoreceptor launch center).
Toxicity Data With Reference
| 1. | ivn-man TDLo:229 µg/kg/I | LANCAO Lancet. 344 (1994),190. | ||
| 2. | ivn-rat LDLo:20 mg/kg | SOLGAV Seminars in Oncology. 19 (Suppl 10)(1992),53. | ||
| 3. | ivn-mus LDLo:2500 µg/kg | SOLGAV Seminars in Oncology. 19 (Suppl 10)(1992),53. | ||
| 4. | ivn-dog LD:>10 mg/kg | SOLGAV Seminars in Oncology. 19 (Suppl 10)(1992),53. |
Safety Profile
A poison by intravenous route. Human systemic effects by intravenous route: jaundice. When heated to decomposition it emits toxic vapors of NOx.
Hazard Codes: 
T
Xi
Risk Statements
R25: Toxic if swallowed.
R36/37/38: Irritating to eyes, respiratory system and skin .
Safety Statements
S45: In case of accident or if you feel unwell, seek medical advice immediately (show label where possible) .
S37/39: Wear suitable gloves and eye/face protection .
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
RIDADR: UN 2811 6.1/PG 3
WGK Germany: 3
RTECS: FE6375500